Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings
FULC·Reported April 27, 2026·Before market open
Diluted EPS came in at $-0.25 (+10.7% YoY), beat the $-0.31 consensus by $0.06.
Diluted EPS
$-0.25beat by $0.06
Consensus: $-0.31
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Fulcrum Therapeutics, Inc.'s Q1 2026 earnings report.
Fulcrum Therapeutics, Inc. (FULC) reported Q1 2026 earnings on April 27, 2026 before market open.
Fulcrum Therapeutics, Inc. reported diluted EPS of $-0.25 for Q1 2026.
EPS beat the consensus estimate of $-0.31 by $0.06.
Compared to the same quarter a year prior, diluted EPS grew 10.7% from $-0.28.
You can read the 8-K earnings release (0001193125-26-178806) and the 10-Q periodic report (0001193125-26-178814) directly on SEC EDGAR. The filing index links above go to sec.gov.